Search results
Results From The WOW.Com Content Network
Lorcaserin, marketed under the brand name Belviq, [4] [5] was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating serotonin receptor the 5-HT 2C receptor in the hypothalamus , a region of the brain which is known to control appetite. [ 6 ]
Lorcaserin (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. [ 11 ] Cannabinoid receptor antagonists were developed to treat obesity because researchers noticed that cannabinoid agonists (such as THC , the main pharmacologically active component ...
[2] [3] Benzarone: 1992 Germany Hepatitis. [3] Benziodarone: 1964 France, UK Jaundice. [3] Beta-ethoxy-lacetanilanide: 1986 Germany Renal toxicity, animal carcinogenicity. [3] Bezitramide: 2004 Netherlands Risk of fatal overdose [10] Bithionol: 1967 US Dermatologic toxicity. [3] Brotizolam: 1989 UK Animal carcinogenicity. [3] Bromfenac: 1998 US
Arena Pharmaceuticals (ARNA) announced, as expected, the U.S. Food and Drug Administration did not approve its weight loss drug Lorcaserin for patients who are obese and overweight because the ...
Lorcaserin is the only agent that has completed phase III clinical trials, and achieved US Food and Drug Administration (FDA) approval. However it was later withdrawn from the market in February 2020 due to a higher risk of malignancy in a randomized trial of lorcaserin. [39] Previously approved agents were subsequently removed from the US ...
Pholcodine can trigger allergic reactions and is common in cough syrups
Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. It works as a serotonin–norepinephrine reuptake inhibitor (SNRI) similar to certain antidepressants.
Lorcaserin is approved for use in adults with a body mass index (BMI) of 30 or greater, which is considered obese, or adults with a BMI of 27 or greater and who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. However, sales of Belviq were disappointing.